EP300 and cancer: A gain of function for CBP and p300 is not wholly unprecedented, as previous data from the Cancer Cell Line Encyclopedia suggested a gain of function for certain CREBBP mutants, specifically truncation mutations located in the TAZ domain, for acetylation at certain histone marks, although this was only identified in a few cell lines26.